繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Congressman Blumenauer Slams DEA For Postponing Marijuana Rescheduling, Places Hope In Soon-To-Be President Harris

2024-08-29 01:43

Congressman Earl Blumenauer, a Democrat from Oregon and co-chair of the Congressional Cannabis Caucus says he’s disappointed the U.S. Drug Enforcement Administration (DEA) chose to delay rescheduling of marijuana.

"It is incredibly disappointing to see the DEA drag their feet on an issue which has been a clear White House priority," the top Democrat said on Tuesday.

The move would likely result in pushing any decision on the matter until after the 2024 election.

Yet, Blumenauer remains optimistic.

  • Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

"While I would have preferred to see rescheduling finalized before the election, we still have every reason to believe that it will happen before President Biden leaves office," he said. "I also have every hope that because of our work together, soon-to-be President Harris will take further steps to rationalize cannabis policy and end the failed war on drugs."

Read Also: Kamala Harris, Tim Walz Form First Explicitly Pro-Cannabis Legalization Presidential Ticket In History

What Happened

On Monday, the DEA announced a delay in rescheduling marijuana. The agency said it would hold an administrative hearing on December 2 when it is expected to gather factual evidence and expert opinions to determine the appropriateness of reclassification. The DEA obtained over 40,000 requests for a hearing on the proposed rule making, which seeks to reclassify marijuana from Schedule I to Schedule III. 

The notice, signed by DEA Administrator Anne Milgram, said that after the agency received notices of intent to participate in the hearing, she would assess them and decide, as reported by Benzinga's Nicolás Jose Rodriguez earlier this week.

The cannabis market was quick to react to the regulatory news with AdvisorShares Pure US Cannabis ETF (NASDAQ:MSOS) dropping over 10% in early trading on Tuesday, while individual cannabis stocks also saw declines.

In the meantime, Blumenauer earlier said moving marijuana from Schedule I to Schedule III is “far from sufficient,” and that more needs to be done in terms of cannabis reform.

“While Schedule III ends criminal penalties attached to Schedule I for marijuana offenses, it does not end mandatory minimums specific to marijuana as a controlled substance or other federal criminal penalties for possession, production, or distribution,” Blumenauer said earlier this year.

Read Also: Congressman Earl Blumenauer On NCAA’s Removal Of Cannabis From Banned Substances List

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。